tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Dae Gon Ha, 51 are a BUY (73.91%), 18 are a HOLD (26.09%).
Analyst Dae Gon Ha, currently employed at STIFEL, carries an average stock price target met ratio of 36.72% that have a potential upside of 28.44% achieved within 102 days.
Dae Gon Ha’s has documented 134 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on EDIT, Editas Medicine at 13-Dec-2024.
Analyst best performing recommendations are on FRLN (FREELINE THERAPEUTICS HOLDINGS PLC).
The best stock recommendation documented was for EDIT (EDITAS MEDICINE) at 5/4/2022. The price target of $15 was fulfilled within 1 day with a profit of $0.81 (5.12%) receiving and performance score of 51.23.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$2
$0.6 (42.86%)
1 years 7 days ago
(18-Dec-2023)
0/2 (0%)
$0.7 (53.85%)
Buy
$2
$0.6 (42.86%)
$36
1 years 5 months 12 days ago
(13-Jul-2023)
0/2 (0%)
$0.59 (41.84%)
Hold
$2
$0.6 (42.86%)
$2
1 years 5 months 13 days ago
(12-Jul-2023)
1/3 (33.33%)
$0.57 (39.86%)
7
Buy
2 years 18 days ago
(07-Dec-2022)
0/2 (0%)
$13.44 (140.59%)
Buy
2 years 7 months 8 days ago
(17-May-2022)
0/1 (0%)
$19.05 (212.85%)
Which stock is Dae Gon Ha is most bullish on?
Which stock is Dae Gon Ha is most reserved on?
What Year was the first public recommendation made by Dae Gon Ha?
